The official logo of Novartis
The Committee for Medicinal Products for Human Use (CHMP) has given Novartis Consentyx™ a positive feedback after being reviewed. Consentyx™ is a recommended medicine for those who are suffering from mild to severe plaque psoriasis in adults. Plaque psoriasis is the common form of psoriasis wherein the skin appears to be raised, red and scaly. A silvery white outer layer covers the patches of the skin that are dry and patchy. These itchy patches can be found anywhere in the body but typically the elbows, knees, lower back and scalp. They can bleed when itched and or aggravated. Other than being itchy and annoying lesions on the skin, psoriasis also poses as a great harm due to other reasons such as diabetes, heart condition or depression. Stress and certain medications can trigger psoriasis and over the counter topical treatments can be bought. Itchy and red parts of the skin that seem to be raised must be checked by a doctor immediately especially when they tend to not go away regardless of other medicines being taken to remove psoriasis.
Medical researches
Research that has been conducted by Novartis has produced amazing results, 70% of patients reacted to the treatment positively and were able to have clear skin within the first 16 weeks of treatment. Consentyx™ has been approved to be sold in Japan, making Japan the first country ever to publicly sell the medicine. Any patients who have psoriasis vulgaris and psoriatic arthritis that do not seem to be responding to medication can purchase this medicine. Around 400,000 people suffer from psoriasis in Japan and this medicine will greatly help and aid in those who have not been living comfortably due to this illness. The market value of Consentyx™ is between US$ 1 billion to US$ 2.5 billion annually. This has been a much needed medicine because of over 125 million people that are affected by psoriasis need immediate treatment. Consentyx™ seems to be very promising and Japan has done a good thing in allowing for this to be sold in the country.
Images from Expert Briefings and Skin Cancer